Medicare reimbursement, working with Congress on legislation relating to the early detection and treatment of deadly diseases.
2025 · 3rd Quarter (July 1 - Sep 30)
TELIX PHARMACEUTICALS US
Filed by LIBERTY PARTNERS GROUP, LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 21, 2025
- Income
- Not reported
- Expenses
- Not reported
- Registrant
- LIBERTY PARTNERS GROUP, LLC
- Client
- TELIX PHARMACEUTICALS US
- Filing UUID
- bb749925-4dee-4f73-a2f5-bc296634e66b
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Medicare reimbursement, working with Congress on legislation relating to the early detection and treatment of deadly diseases.
Medicare reimbursement, working with Congress on legislation relating to the early detection and treatment of deadly diseases.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.